The University of Chicago Header Logo

Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.

Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016 12; 130(3):571-579.

View in: PubMed